eIF4A3-IN-1 is a selective eIF4A3 inhibitor (IC50: 0.26 µM, Kd: 0.043 µM) with cellular nonsense-mediated RNA decay (NMD) inhibitory activity. eIF4A3-IN-1 can specifically bind to the non-ATP binding site of eIF4A3. eIF4A3-IN-1 has anti-tumor and analgesic activities[1][2][3].
